Furthermore, as shown in Figure 6B, the upregulation of RPP40 was a risk factor for DSS in patients with clinical stage III–IV (HR=3.660, P<0.001), histological grade G3 (HR=1.960, P=0.018), a histological type of endometrioid (HR=2.270, P=0.034), age below 60 years old (HR=11.090, P=0.001), BMI less than 30 kg/m2 (HR=2.670, P=0.020), BMI over 30 kg/m2 (HR=2.160, P=0.038), postmenopause status (HR=2.240, P=0.004), the primary therapy outcome of CR (HR=4.350, P=0.001), residual tumor R0 (HR=2.400, P=0.025), or tumor invasion over 50% of the muscular layer (HR=2.800, P=0.004). Here, RPP40 is linked to neoplasm.